| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Paul Jude Tonna last filed a Form 4 in August 2019, as Director at BRTX. Paul Jude Tonna's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 123,850 shares of BRTX. Net of sales, the BRTX filings show accumulation of 87,850 shares.
Paul Jude Tonna has 9 Form 4 filings on record from December 2015 to August 2019, all as Director at BioRestorative Therapies (BRTX), 2015–2019.
The 27 reported transactions were 14 option or other derivative awards, 9 dispositions back to the company, 3 open-market purchases and 1 stock award.
Counted by filing, the open-market trades come to 2 purchases worth about $24K and no sales.
The largest open-market purchase was 70,000 shares of BRTX at an average $0.27 on August 28, 2019, about $19K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2019. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.